8.83
-0.0401(-0.45%)
Currency In USD
| Previous Close | 8.87 |
| Open | 8.95 |
| Day High | 9.03 |
| Day Low | 8.75 |
| 52-Week High | 14.44 |
| 52-Week Low | 3.25 |
| Volume | 349,538 |
| Average Volume | 1.92M |
| Market Cap | 748.91M |
| PE | -16.98 |
| EPS | -0.52 |
| Moving Average 50 Days | 9.84 |
| Moving Average 200 Days | 6.43 |
| Change | -0.04 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $13,199.4 as of February 05, 2025 at a share price of $8.87. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $2,346.56 as of February 05, 2025 at a share price of $8.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
GlobeNewswire Inc.
4 hours ago
Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ETNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
GlobeNewswire Inc.
Jan 27, 2025 12:30 PM GMT
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
GlobeNewswire Inc.
Jan 15, 2025 12:30 PM GMT
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in